BAY-u9773, an antagonist of cysteinyl leukotriene (Cys-LT) receptor, which have equal affinity towards CysLT1 and CysLT2 receptors.
The Cys-LTs are a family of potent bioactive lipids, acting through two distinct G protein-coupled receptors named the CysLT1 and CysLT2 receptors.
To determine the profile of BAY-u9773 as a Cys-LT receptor antagonist, the effect of this component on different smooth muscle preparations was investigated. The result showed that BAY u9773 antagonised 'typical' cysteinyl-leukotriene receptors and inhibited bronchial and venous muscle contractions in the human muscle preparations [1].
BAY-u9773 was also extensively used in animal model to study the function of CysLT1 and CysLT2 receptors. For instance, BAY-u9773 treatment inhibited the infiltration of eosinophil in BAL Fluid in a model of OVA-induced airway hypersensitivity and inflammation in guinea pigs [2]. In addition, this components was shown to act as competitive antagonist towards LTC4 and LTE4 receptors and results in contractions in trachea of guinea pig models [3].
References:
1. Tudhope SR, Cuthbert NJ, Abram TS, Jennings MA, Maxey RJ, Thompson AM, et al. BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. Eur J Pharmacol 1994,264:317-323.
2. Muraki M, Imbe S, Santo H, Sato R, Sano H, Iwanaga T, et al. Effects of a cysteinyl leukotriene dual 1/2 receptor antagonist on antigen-induced airway hypersensitivity and airway inflammation in a guinea pig asthma model. Int Arch Allergy Immunol 2011,155 Suppl 1:90-95.
3. Wikstrom Jonsson E, Rosenqvist U, Dahlen SE. Agonist and antagonist activities of the leukotriene analogue BAY u9773 in guinea pig lung parenchyma. Eur J Pharmacol 1998,357:203-211.